Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | HNF4A | P41235 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874366 | 0.98 | RXRA (0.49) | RXRAPPARGNR1H3HNF4APTPN1 | |
| SCHEMBL5364822 | 0.90 | RXRA (0.48) | RXRAPPARGNR1H3HNF4APTPN1 | |
| SCHEMBL6560607 | 0.86 | RXRA (0.38) | RXRAPPARGNR1H3HNF4APTPN1 | |
| SCHEMBL6033311 | 0.85 | RARA (0.46) | RXRAPPARGNR1H3HNF4ARARA | |
| SCHEMBL8005483 | 0.83 | RXRA (0.50) | RXRAHNF4ARARARARBRARG | |
| SCHEMBL8461877 | 0.81 | RXRA (0.65) | RXRAPPARGNR1H3HNF4ARARA | |
| SCHEMBL8037984 | 0.81 | RXRA (0.36) | RXRAPPARGNR1H3HNF4APTPN1 | |
| SCHEMBL6033082 | 0.80 | RXRA (0.43) | RXRAPPARGNR1H3HNF4ARARA | |
| SCHEMBL7212199 | 0.79 | THRA (0.38) | RXRAPPARGNR1H3HNF4APTPN1 | |
| SCHEMBL2038965 | 0.79 | THRA (0.47) | THRATHRBKDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-0862554-B1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | disclosed |
| EP-0947496-A1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | Galderma Research & Development, S.N.C. (FR) | 1999-10-06 | — | — | EP | disclosed |
| US-5958956-A | SKIN DISORDERS; WOUND HEALING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0862554-A1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-09 | — | — | EP | disclosed |
| US-5726191-A | TREATEMENT OF LIGHT AND AGE DAMAGED SKIN | HOFFMANN-LA ROCHE INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1997018192-A1 | AROMATIC CARBOXYLIC ACID ESTERS, THE PRODUCTION OF SAME AND USE OF SAME AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | RXRA 174/4885PPARG 61/4885NR1H3 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.